Telomir Pharms Stock Price, News & Analysis

Telomir Pharmaceuticals (NASDAQ:TELO) has announced promising preclinical results for its lead compound Telomir-1 in treating mitochondrial dysfunction. The study, conducted with Smart Assays Biotechnologies, demonstrated that Telomir-1 successfully restored mitochondrial function in Hutchinson-Gilford Progeria Syndrome (HGPS) cells without triggering oxidative stress or cell proliferation.

Key findings show that Telomir-1 increased mitochondrial energy production, reduced reactive oxygen species (ROS), and showed stronger effects in diseased cells compared to healthy controls. The compound's unique profile suggests potential applications in treating neurodegenerative conditions including Parkinson's, Alzheimer's, and ALS, where mitochondrial failure drives disease progression.

The company is currently finalizing IND-enabling work and evaluating potential clinical indications for Telomir-1's development pathway.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical findings for its Telomir-1 drug candidate in treating aggressive prostate cancer. The study demonstrated that Telomir-1 successfully reversed epigenetic gene silencing of STAT1, a crucial tumor suppressor, outperforming both Paclitaxel and Rapamycin in PC3 xenograft models.

The drug showed superior efficacy in a 21-day oral administration trial, fully reversing STAT1 hypermethylation in a dose-dependent manner. Additionally, Telomir-1 reduced hypermethylation of TMS1, another key tumor suppressor, while maintaining a favorable safety profile by not elongating telomeres in cancerous cells.

These findings build upon previous March 2025 results where Telomir-1 reduced tumor volume by approximately 50% and eliminated chemotherapy-induced mortality when combined with Paclitaxel.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced promising preclinical data showing its lead candidate, Telomir-1, successfully prevented cellular aging in human progeria cell lines. The study, conducted by Smart Assays using cells from the Progeria Research Foundation, demonstrated significant improvements in cell viability, reduction of oxidative stress, and restoration of mitochondrial function. Progeria (HGPS) is an ultra-rare genetic disorder affecting 400-500 people worldwide, causing rapid aging in children with an average life expectancy of 13-15 years. The current FDA-approved treatment, Zokinvy, only extends lifespan by 4.3 years without addressing underlying disease mechanisms. Telomir-1 showed effectiveness in regulating intracellular metal ions, reducing oxidative stress, restoring mitochondrial function, and addressing other critical aging pathways. The company is finalizing IND-enabling studies and plans to engage with the FDA for potential orphan drug designation.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough preclinical results for Telomir-1 in treating Wilson's disease, a rare genetic disorder causing copper accumulation. In ATP7B C271X -/- zebrafish models, the drug demonstrated significant dose-dependent improvements including 4-5x reduction in tremors, 50% reduction in liver copper accumulation, and normalization of critical liver biomarkers (ALT, AST, bilirubin). The treatment reversed neurological symptoms, liver and kidney damage, while improving survival rates. These results build upon previous successful studies in Werner syndrome and Age-Related Macular Degeneration, highlighting Telomir-1's broad therapeutic potential. The company plans to file its first IND by end of 2025, with human clinical trials scheduled for early 2026.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical results for Telomir-1 in treating Werner Syndrome, a rare genetic aging disorder. The study, conducted using a zebrafish model, demonstrated remarkable anti-aging effects including three-fold telomere lengthening, DNA methylation reversal, and complete survival rates. The oral treatment restored muscle mass and body weight in affected animals, which typically show 50-60% reductions, back to normal levels. Additionally, Telomir-1 reduced oxidative stress by up to 50% and achieved 100% survival rate compared to 15% mortality in untreated animals. The drug showed potential in reversing key aging markers by resetting the body's epigenetic clock and restoring youthful gene regulation. These findings build upon previous successful results in C. elegans studies and position Telomir-1 as a promising therapeutic candidate for aging-related diseases.

Telomir Pharmaceuticals (NASDAQ:TELO) announced its participation in BIO 2025 in Boston as it prepares for IND submission of Telomir-1, a novel small molecule designed to elongate telomeres and reverse biological aging. The company plans to begin human dosing in H1 2026 and is advancing a rare-disease strategy focusing on conditions like Werner's syndrome, Wilson's disease, Progeria, and Dysphonia. Telomir-1 has shown promising preclinical results across multiple therapeutic areas, including vision restoration, longevity, metabolic disease, and oncology. In prostate cancer models, Telomir-1 reduced tumor growth by 50% while protecting healthy cells. The company is also developing Telomir-Ag2 for multidrug-resistant bacteria. Management will explore strategic collaborations, licensing opportunities, and potential M&A transactions during the conference.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough preclinical results for Telomir-1, their oral therapeutic for age-related macular degeneration (AMD). In a 14-day study using a genetically modified zebrafish model, Telomir-1 demonstrated remarkable vision restoration and retinal regeneration capabilities. The study showed significant improvements in multiple FDA-recognized surrogate endpoints. Key results include: restoration of vision and coordinated swimming behavior, complete recovery of inner nuclear layer thickness, improved ganglion cell layer integrity, 50% reduction in reactive oxygen species levels, and zero mortality in treatment groups. The zebrafish model exhibited 15% retinal degeneration pre-treatment, affecting critical retinal layers. This breakthrough represents a potential paradigm shift in AMD treatment, as no oral drug has previously demonstrated such comprehensive retinal restoration and vision recovery in AMD models.

Telomir Pharmaceuticals (NASDAQ:TELO) has secured $3 million in equity financing through a direct investment from The Bayshore Trust at $3.00 per share, an 18% premium to the market price. This follows a previous $1 million investment at $7.00 per share and complements a $5 million undrawn credit line. The company is advancing two key drug candidates: Telomir-1, a first-in-class age-reversal molecule targeting cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound for drug-resistant infections. Telomir-1 has shown promising preclinical results in multiple indications including Progeria, Type 2 diabetes, Wilson's disease, and oncology. The company plans to submit an IND by year-end, focusing on a rare disease indication to efficiently demonstrate clinical impact.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced Telomir-Ag2 as a novel drug candidate for treating bacterial infections, including drug-resistant pathogens. The breakthrough involves stabilizing Silver(II) in a biologically compatible form using their Telomir-1 platform. In preclinical studies, Telomir-Ag2 showed broad-spectrum antimicrobial activity against various pathogens, including MARSA. The compound targets a significant market opportunity, with the silver wound dressings market projected to reach $1.36 billion by 2030 and the antimicrobial coatings market expected to grow to $33.7 billion by 2031. MARSA alone causes over 323,000 hospitalizations and 10,000 deaths annually in the US. The company plans to advance Telomir-Ag2 into formulation development and IND-enabling studies.